Newsletters
Dr. Weisman and His Patients Featured in Article About MCI
In neurology we learn the same lessons again and again: Time is brain.
ANA Featured in Washington Post Article About Leqembi
Lecanemab has not been as widely tested in Black patients.
Dr. Weisman Quoted in Article about Quest Rapid Alzheimer’s Test
Almost anyone can take this quick test for Alzheimer’s without even going to the doctor. It’s a terrible idea.
An Open Letter to Highmark and Independence Blue Cross
Denial of coverage for lecanemab will have devastating consequences for millions of patients and families.
FDA Converts Lecanemab to Traditional Approval
Leqembi is the first amyloid beta-directed antibody to be converted from an accelerated approval to a traditional approval for the treatment of Alzheimer’s disease.
Dr. Weisman Quoted in Philadelphia Inquirer Article about Tofersen
On March 22, Weisman and his fellow advisers voted unanimously that the drug was ‘reasonably likely’ to prove beneficial, paving the way for the agency to approve it Tuesday.